Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
15.01
+0.36 (2.46%)
At close: May 12, 2025, 4:00 PM
14.55
-0.46 (-3.06%)
After-hours: May 12, 2025, 6:16 PM EDT

Mineralys Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
25.7823.8214.35.232.420.53
Research & Development
175.71168.5870.3626.2516.312.41
Operating Expenses
201.49192.484.6631.4818.732.94
Operating Income
-201.49-192.4-84.66-31.48-18.73-2.94
Interest Expense
-----0.03-0.12
Interest & Investment Income
12.9714.5912.761.68--
Other Non Operating Income (Expenses)
00.01000-0.37
EBT Excluding Unusual Items
-188.51-177.81-71.9-29.8-18.75-3.43
Other Unusual Items
-----0.66-
Pretax Income
-188.51-177.81-71.9-29.8-19.41-3.43
Net Income
-188.51-177.81-71.9-29.8-19.41-3.43
Net Income to Common
-188.51-177.81-71.9-29.8-19.41-3.43
Shares Outstanding (Basic)
514936555
Shares Outstanding (Diluted)
514936555
Shares Change (YoY)
22.76%34.13%600.33%3.67%7.64%-
EPS (Basic)
-3.73-3.66-1.99-5.77-3.89-0.74
EPS (Diluted)
-3.73-3.66-1.99-5.77-3.89-0.74
Free Cash Flow
--166.41-81.17-29.22-14.56-2.46
Free Cash Flow Per Share
--3.43-2.24-5.66-2.92-0.53
EBITDA
-201.44-192.36----
D&A For EBITDA
0.050.04----
EBIT
-201.49-192.4-84.66-31.48-18.73-2.94
Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q